Clinical research
CHARACTERIZATION OF ASTROCYTE REACTIVITY WITH [18F]F-DED PET IN NEURODEGENERATIVE DISEASES
Cross-sectional, single-arm Phase II clinical trial using [18F] fluorodeprenyl-D2 PET in individuals at different stages of Alzheimer’s disease.
Specific objectives
- To acquire [18F]F-DED PET in participants of the Barcelona-based cohorts, as detailed in section 4.4.
- To characterize [18F]F-DED uptake in participants within the AD continuum and other neurodegenerative diseases.
Secondary objectives
- To study the role of [18F]F-DED uptake on different AD disease stages and neurodegenerative diseases.
- To define the relationship between [18F]F-DED uptake and known risk factors for ADRD.
- To study the relation between [18F]F-DED uptake and core neurodegenerative-related pathologies.
- To explore methodological aspects influencing the quantification of [18F]F-DED and its applicability in a clinical context.
Participation of Ace Alzheimer Center Barcelona
Ace Alzheimer Center Barcelona participates in the recruitment of 32 participants diagnosed with mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease. The project involves Dr. Mercè Boada and Dr. Marta Marquié from Ace.
